"In that vein, we have formed the Tempus Advisory Board which solidifies this intent and overall mission. We are thrilled to gather this group of internationally renowned, experienced, and passionate ...

The partners plan to build evidence packages that standardize comprehensive genomic profiling and other molecular testing ...

Both TEM and DOCS are technology-intensive healthcare companies leveraging artificial intelligence to enhance their platforms ...

Former House Speaker Nancy Pelosi's stock portfolio has taken a major hit in 2025, aligning with the broader market sell-off.

We recently published a list of 10 Stocks That Will Profit From AI. In this article, we are going to take a look at where ...

In February 2025, Tempus AI, Inc. (NASDAQ:TEM) completed the acquisition of Ambry Genetics, enhancing its capabilities in genetic testing and data services. Tempus’s stock has experienced ...

Deep 6’s advanced algorithms complement Tempus AI’s existing platform, strengthening its foothold in AI-driven healthcare. The February 2025 acquisition of Ambry Genetics further expanded its ...

The Top 30's only gainers in March were Fulgent Genetics (+9 percent), Qiagen (+5 percent), and Becton Dickinson (+2 percent). The largest decliners were Grail (-34 percent), CareDx (-20 percent), and ...

“Tempus is committed to enabling clinicians to provide better ... including our ability to realize the expected benefits of the acquisition of Ambry Genetics; the potential adverse impact of climate ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading ... including our ability to realize the expected benefits of the acquisition of Ambry Genetics; the potential adverse impact of climate ...

But the company could not build a sustainable business and many of the 15 million people who gave their genetic information to the platform are worried about where their personal data could end up.